1 – 10 of 213
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta
(
- Contribution to journal › Article
-
Mark
Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice
(
- Contribution to journal › Article
-
Mark
Benchmarking Alzheimer’s disease prediction : personalised risk assessment using polygenic risk scores across various methodologies and genome-wide studies
(
- Contribution to journal › Article
-
Mark
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
(
- Contribution to journal › Article
-
Mark
Machine learning prediction of tau-PET in Alzheimer's disease using plasma, MRI, and clinical data
(
- Contribution to journal › Article
-
Mark
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals : implications for clinical trials
(
- Contribution to journal › Article
-
Mark
Tau, atrophy, and domain-specific cognitive impairment in typical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers : a longitudinal cohort study
(
- Contribution to journal › Article
-
Mark
Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers
2025) In Nature Medicine(
- Contribution to journal › Article